FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

71 letters match. Newest first.

  1. Active Cosmetics Manufacturing Inc.

    FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.

    High risk
  2. Respilon Production S.R.O.

    FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.

    Medium
  3. Foshan Miwei Cosmetics Co., Ltd.

    FDA warns Foshan Miwei Cosmetics over manufacturing practice failures and unapproved, misbranded over-the-counter (OTC) sunscreen drugs; drugs on import alert.

    High risk
  4. Lexia LLC

    FDA cited Lexia for manufacturing violations in an OTC topical pain relief drug, including missing release and component testing.

    High risk
  5. Xiamen Kang Zhongyuan Biotechnology Co., Ltd.

    FDA found filthy conditions and falsified records at Chinese drug maker Xiamen Kang Zhongyuan; cough drops recalled, imports blocked.

    High risk
  6. Chemco Corporation

    FDA warns Chemco Corporation about CGMP failures and unapproved, misbranded OTC drug products from its Miami Lakes facility.

    High risk
  7. Yangzhou H&R Plastic Daily Chemical Co., Ltd.

    Yangzhou H&R Plastic Daily Chemical, a Chinese contract manufacturer, lacked release testing and CGMP controls for its OTC drug.

    High risk
  8. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug manufacturer, was cited for insanitary conditions and CGMP violations after a 2025 FDA inspection.

    High risk
  9. OraLabs, Inc.

    FDA warned OraLabs, an OTC drugmaker in Parker, Colorado, that it skipped microbial release testing and dismissed contamination findings.

    High risk
  10. JZ Wholesale, Inc.

    FDA warned JZ Wholesale after finding widespread rodent and insect contamination in food at its Fort Smith, Arkansas warehouse.

    High risk
  11. Fareva Morton Grove

    FDA found microbial contamination risks and data integrity failures at Fareva Morton Grove's OTC drug manufacturing.

    High risk
  12. Bio-Medical Pharmaceutical Manufacturing Corporation

    Bio-Medical Pharmaceutical Manufacturing, a Houston contract manufacturer, was cited for sterile OTC drug current good manufacturing practice (CGMP) failures and drug listing violations.

    High risk
  13. Signature Formulations, LLC

    FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

    High risk
  14. HTO Nevada, Inc. dba Kirkman

    HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.

    High risk
  15. Fulijaya Manufacturing SDN. BHD.

    Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.

    High risk
  16. Integrity Partners Group

    FDA warns Integrity Partners Group about manufacturing failures at its Chemisphere drug plant, including inadequate testing, supplier verification, cleaning, and process validation.

    High risk
  17. Absolutely Natural

    FDA warned Absolutely Natural of Melbourne, Florida, over nonprescription drug manufacturing violations, including weak contamination investigations and component testing.

    High risk
  18. Tower Laboratories Ltd.

    FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

    High risk
  19. LiquidCapsule Manufacturing, LLC

    LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.

    High risk
  20. Private Label Skin Care, Inc.

    FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.

    High risk
  21. SV Labs Corporation

    SV Labs released microbe-contaminated OTC drug products and lacked water, process and quality controls, FDA says.

    High risk